









Markets
/
Stocks
/
nasdaq-uthr
/

United Therapeutics Corp

UTHR

440.000USD

-5.380-1.21%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

19.89BMarket Cap

16.02P/E TTM



United Therapeutics Corp

440.000

-5.380-1.21%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of United Therapeutics Corp

Currency: USD Updated: 2025-10-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

United Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

6 / 173

Overall Ranking

21 / 4697

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 16 analysts

Buy

Current Rating

489.804

Target Price

+11.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

United Therapeutics Corp Highlights

StrengthsRisks

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 48.60% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.32.

Overvalued

The company’s latest PE is 15.89, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 44.91M shares, decreasing 6.50% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 14.70K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.70.

Financial Health

Currency: USD Updated: 2025-10-10

The company's current financial score is 9.13, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 798.60M, representing a year-over-year increase of 11.71%, while its net profit experienced a year-over-year increase of 11.29%.

Score

Industry at a Glance

Previous score

9.13

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

United Therapeutics Corp's Company Valuation

Currency: USD Updated: 2025-10-10

The company’s current valuation score is 7.74, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 15.89, which is 12.96% below the recent high of 17.95 and 37.57% above the recent low of 9.92.

Score

Industry at a Glance

Previous score

7.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-10

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for United Therapeutics Corp is 500.00, with a high of 580.00 and a low of 402.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 16 analysts

Buy

Current Rating

489.804

Target Price

+11.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

182

Total

Median

Average

Company name

Ratings

Analysts

United Therapeutics Corp

UTHR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-10

The company’s current price momentum score is 9.16, which is higher than the Pharmaceuticals industry's average of 6.79. Sideways: Currently, the stock price is trading between the resistance level at 467.61 and the support level at 404.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.27

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-4.825

Neutral

RSI(14)

61.898

Neutral

STOCH(KDJ)(9,3,3)

65.292

Sell

ATR(14)

13.637

Low Volatility

CCI(14)

23.997

Neutral

Williams %R

41.929

Buy

TRIX(12,20)

0.832

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

448.886

Sell

MA10

442.264

Sell

MA20

430.023

Buy

MA50

372.058

Buy

MA100

335.590

Buy

MA200

331.766

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 99.30%, representing a quarter-over-quarter decrease of 3.24%. The largest institutional shareholder is The Vanguard, holding a total of 4.43M shares, representing 9.79% of shares outstanding, with 1.15% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

4.43M

-0.20%

BlackRock Institutional Trust Company, N.A.

4.34M

-3.10%

Avoro Capital Advisors LLC

2.37M

-11.40%

State Street Global Advisors (US)

2.17M

-2.83%

Renaissance Technologies LLC

Star Investors

2.12M

+0.57%

Wellington Management Company, LLP

1.44M

-28.79%

AQR Capital Management, LLC

1.27M

+40.15%

Geode Capital Management, L.L.C.

1.20M

-1.93%

LSV Asset Management

864.62K

-4.18%

Invesco Capital Management LLC

Star Investors

821.69K

+118.44%

Risk Assessment

Currency: USD Updated: 2025-10-10

The company’s current risk assessment score is 6.17, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.